MGMT and neoplasm: C8I hydrolyses to liberate a stable intermediate that methylates O6-guanine resulting in GBM- and CRC cytotoxicity in the presence of MGMT and MMR-loss; (2) TMZ has been encapsulated within biocompatible AFt protein cages [Table 4] to enhance transit across the BBB and facilitate efficient delivery to the site of the tumour.